

Europe Pancreatic Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-01-01 | 402 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

The Europe pancreatic cancer diagnostics market is projected to register a substantial CAGR of 7.6% from 2023 to 2030. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2023 to 2030.

Market Segmentation:

Europe Pancreatic Cancer Diagnostics Market, By Test Type (Imaging Test, Biopsy, Blood Test, Genomic Test, and Others), Cancer Stage (Stage 0, Stage I, Stage II, Stage III and Stage IV), Tumor Type(Exocrine Tumors and Neuroendocrine Tumors), Product (Instrument-Based Products, Platform-Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application(Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland and the Rest of Europe) Industry Trends and Forecast to 2030

Some of the major factors contributing to the growth of pancreatic cancer diagnostics market are:

- Rise in prevalence and incidence of pancreatic cancer
- Increase in awareness about the pancreatic cancer diagnostics

Market Players:

Some of the major players operating in the Europe pancreatic cancer diagnostics market are:

- Canon Medical Systems ANZ Pty Limited.
- Koninklijke Philips N.V.
- Siemens Healthcare Private Limited
- Grail
- Myriad Genetics, Inc.
- BD
- Abbott

Scotts International, EU Vat number: PL 6772247784

- Agilent Technologies, Inc.
- Thermo Fisher Scientific
- QIAGEN
- MP BIOMEDICALS
- Laboratory Corporation of America Holdings
- DiaSource
- Creative Biolabs
- Meridian Life Science, Inc.

Table of Contents:

TABLE OF CONTENTS

- 1 INTRODUCTION 91
- 1.1 OBJECTIVES OF THE STUDY 91
- 1.2 MARKET DEFINITION 91
- 1.3 OVERVIEW OF THE EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET 91
- 1.4 CURRENCY AND PRICING 94
- 1.5 LIMITATIONS 94
- 1.6 MARKETS COVERED 94
- 2 MARKET SEGMENTATION 98
- 2.1 MARKETS COVERED 98
- 2.2 GEOGRAPHICAL SCOPE 99
- 2.3 YEARS CONSIDERED FOR THE STUDY 100
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 101
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 104
- 2.6 MULTIVARIATE MODELLING 105
- 2.7 MARKET END USER COVERAGE GRID 106
- 2.8 PRODUCT LIFELINE CURVE 107
- 2.9 DBMR MARKET POSITION GRID 108
- 2.10 VENDOR SHARE ANALYSIS 109
- 2.11 SECONDARY SOURCES 110
- 2.12 ASSUMPTIONS 110
- 3 EXECUTIVE SUMMARY 111
- 4 PREMIUM INSIGHTS 114
- 4.1 PESTEL ANALYSIS 115
- 4.2 PORTER'S FIVE FORCES MODEL 116
- 5 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHTS 117
- 6 EPIDEMIOLOGY 119
- 7 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, REGULATIONS 120
- 8 MARKET OVERVIEW 123
- 8.1 DRIVERS 125
- 8.1.1 GROW IN PREVALENCE OF PANCREATIC CANCER 125
- 8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN PANCREATIC DIAGNOSTICS 125
- 8.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 126
- 8.1.4 INCREASE IN AWARENESS REGARDING PANCREATIC CANCER 126
- 8.2 RESTRAINTS 127
- 8.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF PANCREATIC CANCER

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

DIAGNOSTIC PRODUCTS 127

- 8.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF PANCREATIC CANCER 127
- 8.3 OPPORTUNITIES 128
- 8.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR PANCREATIC CANCER 128
- 8.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 129
- 8.3.3 GOVERNMENT INITIATIVES TOWARD PANCREATIC CANCER DIAGNOSTICS 129
- 8.4 CHALLENGES 130
- 8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 130
- 8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 130
- 9 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE 131
- **9.1 OVERVIEW 132**
- 9.2 IMAGING TEST 135
- 9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 136
- 9.2.2 MAGNETIC RESONANCE IMAGING (MRI) 136
- 9.2.2.1 MR CHOLANGIOPANCREATOGRAPHY 136
- 9.2.2.2 MR ANGIOGRAPHY (MRA) 137
- 9.2.3 ULTRASOUND 137
- 9.2.3.1 ABDOMINAL ULTRASOUND 137
- 9.2.3.2 ENDOSCOPIC ULTRASOUND (EUS) 137
- 9.2.4 CHOLANGIOPANCREATOGRAPHY 137
- 9.2.4.1 MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY (MRCP) 138
- 9.2.4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) 138
- 9.2.4.3 PRECUTANEOUS TRANSHEPTIC CHOLANGIOPANCREATOGRAPHY (PTC) 138
- 9.2.5 POSITRON EMISSION TOMOHRAPHY (PET) 138
- 9.2.6 OTHERS 138
- 9.3 BIOPSY 139
- 9.3.1 CT-GUIDED NEEDLE BIOPSY 140
- 9.3.2 FINE NEEDLE ASPIRATION (FNA) 140
- 9.3.3 CORE NEEDLE BIOPSY 140
- 9.3.4 OTHERS 140
- 9.4 BLOOD TEST 140
- 9.4.1 LIVER FUNCTION TEST 141
- 9.4.2 TUMOR MARKER 141
- 9.4.2.1 CA 19-9 BIOMARKER TEST 142
- 9.4.2.2 CARCINOEMBROYNIC ANTIGEN (CEA) TEST 142
- 9.4.2.3 CA 50 MARKER TEST 142
- 9.4.2.4 OTHERS 142
- 9.4.3 OTHERS 142
- 9.5 GENOMIC TEST 143
- 9.6 OTHERS 144
- 10 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 145
- 10.1 OVERVIEW 146
- 10.2 STAGE IV 149
- 10.3 STAGE III 149
- 10.4 STAGE II 150
- 10.4.1 STAGE IIA 151
- 10.4.2 STAGE IIB 151

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.5 STAGE | 151
- 10.5.1 STAGE IA 152
- 10.5.2 STAGE IB 152
- 10.6 STAGE 0 153
- 11 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 154
- 11.1 OVERVIEW 155
- 11.2 EXOCRINE TUMORS 158
- 11.2.1 INSTRUMENT-BASED PRODUCTS 159
- 11.2.2 PLATFORM-BASED PRODUCTS 159
- 11.2.3 KITS AND REAGENTS 159
- 11.2.4 OTHER CONSUMABLES 159
- 11.3 NEUROENDOCRINE TUMORS 159
- 11.3.1 INSTRUMENT-BASED PRODUCTS 160
- 11.3.2 PLATFORM-BASED PRODUCTS 160
- 11.3.3 KITS AND REAGENTS 161
- 11.3.4 OTHER CONSUMABLES 161
- 12 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT 162
- 12.1 OVERVIEW 163
- 12.2 INSTRUMENT-BASED PRODUCTS 166
- 12.2.1 IMAGING 167
- 12.2.2 BIOPSY 167
- 12.3 PLATFORM-BASED PRODUCTS 167
- 12.3.1 NEXT-GENERATION SEQUENCING 168
- 12.3.2 MICROARRAYS 168
- 12.3.3 PCR 168
- 12.3.4 OTHERS 169
- 12.4 KITS AND REAGENTS 169
- 12.4.1 CA19-9 PANCREATIC CANCER TEST KITS 170
- 12.4.1.1 ELISA TEST KITS 170
- 12.4.1.2 CASETTE TEST KITS 170
- 12.4.1.3 OTHERS 170
- 12.4.2 CEA PANCREATIC CANCER TEST KITS 171
- 12.4.2.1 ELISA TEST KITS 171
- 12.4.2.2 CASETTE TEST KITS 171
- 12.4.2.3 OTHERS 171
- 12.5 OTHER CONSUMABLES 171
- 13 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 173
- 13.1 OVERVIEW 174
- 13.2 FLUORESCENT IN SITU HYBRIDIZATION 177
- 13.3 NEXT GENERATION SEQUENCING 178
- 13.4 FLUORIMMUNOASSAY 179
- 13.5 COMPARATIVE GENOMIC HYBRIDIZATION 180
- 13.6 IMMUNOHISTOCHEMICAL 181
- 13.7 OTHERS 182
- 14 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION 183
- 14.1 OVERVIEW 184
- **14.2 SCREENING 187**

Scotts International. EU Vat number: PL 6772247784

- 14.2.1 INSTRUMENT-BASED PRODUCTS 188
- 14.2.2 PLATFORM-BASED PRODUCTS 188
- 14.2.3 KITS AND REAGENTS 188
- 14.2.4 OTHER CONSUMABLES 188
- 14.3 DIAGNOSTIC AND PREDICTIVE 188
- 14.3.1 INSTRUMENT-BASED PRODUCTS 189
- 14.3.2 PLATFORM-BASED PRODUCTS 189
- 14.3.3 KITS AND REAGENTS 189
- 14.3.4 OTHER CONSUMABLES 189
- 14.4 PROGNOSTIC 190
- 14.4.1 INSTRUMENT-BASED PRODUCTS 191
- 14.4.2 PLATFORM-BASED PRODUCTS 191
- 14.4.3 KITS AND REAGENTS 191
- 14.4.4 OTHER CONSUMABLES 191
- 14.5 RESEARCH 191
- 14.5.1 INSTRUMENT-BASED PRODUCTS 192
- 14.5.2 PLATFORM-BASED PRODUCTS 192
- 14.5.3 KITS AND REAGENTS 192
- 14.5.4 OTHER CONSUMABLES 192
- 15 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER 193
- 15.1 OVERVIEW 194
- 15.2 HOSPITALS 197
- 15.3 DIAGNOSTIC CENTERS 197
- 15.4 CANCER RESEARCH CENTERS 198
- 15.5 ACADEMIC INSTITUTES 199
- 15.6 AMBULATORY SURGICAL CENTERS 200
- 15.7 OTHERS 201
- 16 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 202
- 16.1 OVERVIEW 203
- 16.2 DIRECT TENDER 206
- 16.3 RETAIL SALES 207
- 16.4 OTHERS 208
- 17 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION 209
- 17.1 EUROPE 210
- 17.1.1 GERMANY 225
- 17.1.2 FRANCE 234
- 17.1.3 UNITED KINGDOM 243
- 17.1.4 ITALY 252
- 17.1.5 SPAIN 261
- 17.1.6 RUSSIA 270
- 17.1.7 NETHERLANDS 279
- 17.1.8 POLAND 288
- 17.1.9 SWITZERLAND 297
- 17.1.10 BELGIUM 306
- 17.1.11 SWEDEN 315
- 17.1.12 NORWAY 324
- 17.1.13 DENMARK 333

Scotts International. EU Vat number: PL 6772247784

17.1.14 FINLAND 342

17.1.15 TURKEY 351

17.1.16 REST OF EUROPE 360

18 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 361

18.1 COMPANY SHARE ANALYSIS: EUROPE 361

19 SWOT ANALYSIS 362

20 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET 363

20.1 CANON MEDICAL SYSTEMS CORPORATION 363

20.1.1 COMPANY SNAPSHOT 363

20.1.2 REVENUE ANALYSIS 363

20.1.3 COMPANY SHARE ANALYSIS 364

20.1.4 PRODUCT PORTFOLIO 364

20.1.5 RECENT DEVELOPMENT 364

20.2 KONINKLIJKE PHILIPS N.V. 365

20.2.1 COMPANY SNAPSHOT 365

20.2.2 REVENUE ANALYSIS 365

20.2.3 COMPANY SHARE ANALYSIS 366

20.2.4 PRODUCT PORTFOLIO 366

20.2.5 RECENT DEVELOPMENTS 366

20.3 SIEMENS HEALTHCARE GMBH 368

20.3.1 COMPANY SNAPSHOT 368

20.3.2 REVENUE ANALYSIS 368

20.3.3 COMPANY SHARE ANALYSIS 369

20.3.4 PRODUCT PORTFOLIO 369

20.3.5 RECENT DEVELOPMENT 370

20.4 GRAIL 371

20.4.1 COMPANY PROFILE 371

20.4.2 COMPANY SHARE ANALYSIS 371

20.4.3 PRODUCT PORTFOLIO 372

20.4.4 RECENT DEVELOPMENT 372

20.5 MYRIAD GENETICS, INC. 373

20.5.1 COMPANY SNAPSHOT 373

20.5.2 REVENUE ANALYSIS 373

20.5.3 COMPANY SHARE ANALYSIS 374

20.5.4 PRODUCT PORTFOLIO 374

20.5.5 RECENT DEVELOPMENT 374

20.6 BD 375

20.6.1 COMPANY SNAPSHOT 375

20.6.2 REVENUE ANALYSIS 375

20.6.3 PRODUCT PORTFOLIO 376

20.6.4 RECENT DEVELOPMENT 376

20.7 BODITECH MED INC. 377

20.7.1 COMPANY PROFILE 377

20.7.2 PRODUCT PORTFOLIO 377

20.7.3 RECENT DEVELOPMENT 377

20.8 ABBOTT (2022) 378

20.8.1 COMPANY SNAPSHOT 378

Scotts International. EU Vat number: PL 6772247784

20.8.2 REVENUE ANALYSIS 378

20.8.3 PRODUCT PORTFOLIO 379

20.8.4 RECENT DEVELOPMENT 379

20.9 FUJIFILM HOLDINGS AMERICA CORPORATION 380

20.9.1 COMPANY SNAPSHOT 380

20.9.2 REVENUE ANALYSIS 380

20.9.3 PRODUCT PORTFOLIO 381

20.9.4 RECENT DEVELOPMENT 381

20.10 ACCUBIOTECH CO., LTD. 382

20.10.1 COMPANY PROFILE 382

20.10.2 PRODUCT PORTFOLIO 382

20.10.3 RECENT DEVELOPMENTS 382

20.11 AGILENT TECHNOLOGIES, INC. 383

20.11.1 COMPANY PROFILE 383

20.11.2 REVENUE ANALYSIS 383

20.11.3 PRODUCT PORTFOLIO 384

20.11.4 RECENT DEVELOPMENT 384

20.12 CREATIVE BIOLABS. 385

20.12.1 COMPANY PROFILE 385

20.12.2 PRODUCT PORTFOLIO 385

20.12.3 RECENT DEVELOPMENT 385

20.13 CTK BIOTECH, INC. 386

20.13.1 COMPANY PROFILE 386

20.13.2 PRODUCT PORTFOLIO 386

20.13.3 RECENT DEVELOPMENT 386

20.14 DIASOURCE 387

20.14.1 COMPANY SNAPSHOT 387

20.14.2 PRODUCT PORTFOLIO 387

20.14.3 RECENT DEVELOPMENT 387



Print this form

To place an Order with Scotts International:

 $\hfill \Box$ - Complete the relevant blank fields and sign

Europe Pancreatic Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-01-01 | 402 pages | Data Bridge Market Research

RDER FORM:				
elect license	License			Price
	Single User License			\$3500.00
	Corporate Users License			\$4200.00
			VAT	
			Total	
Please circle the relev	ant license ontion. For any questions of	ease contact support@	escotts-international.com or 0048 603 3	94 346
			companies who are unable to provide a	
VAT WIII be added to	t 25% for 1 onsir based companies, indi	viduais and Lo based (companies who are unable to provide a	valid LO va
· · · · · · · · · · · · · · · · · · ·		Phone*		
irst Name*		Last Name*		_
l		Last Hame		
ob title*				
Company Name*		EU Vat / Tax ID /	NIP number*	
Address*		City*		
Zip Code*		Country*		
		Date	2025-05-13	
		Signature		
		Signature		